← Back to Screener
Immuron Limited American Depositary Shares (IMRN)
Price$0.84
Favorite Metrics
Price vs S&P 500 (26W)-68.18%
Price vs S&P 500 (4W)-15.20%
Market Capitalization$6.55M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)2.21x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)111.96%
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)-20.13%
Gross Margin (TTM)63.68%
Net Profit Margin (TTM)-62.14%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-0.01
Revenue Growth (5Y)23.67%
EPS (Annual)$-0.02
ROI (Annual)-64.64%
Gross Margin (Annual)65.39%
Net Profit Margin (5Y Avg)-1309.47%
Cash / Share (Quarterly)$0.02
Revenue Growth QoQ (YoY)4.76%
ROA (Last FY)-51.49%
Revenue Growth TTM (YoY)14.30%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-36.64%
Operating Margin (TTM)-63.91%
Cash Flow / Share (Annual)$-0.02
P/B Ratio0.70x
P/B Ratio (Quarterly)0.95x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-0.11x
Net Interest Coverage (TTM)-13.28x
ROA (TTM)-36.78%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)5.09x
Quick Ratio (Quarterly)6.83x
3-Month Avg Trading Volume0.71M
52-Week Price Return3.85%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)1.26x
Asset Turnover (Annual)0.72x
52-Week High$0.10
Operating Margin (5Y Avg)-1312.09%
EPS Excl Extra (Annual)$-0.02
Tangible BV CAGR (5Y)18.38%
26-Week Price Return-64.20%
Quick Ratio (Annual)4.19x
13-Week Price Return-19.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.04x
Enterprise Value$-0.608
Revenue / Share Growth (5Y)17.18%
Asset Turnover (TTM)0.59x
Book Value / Share Growth (5Y)1.71%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.50x
Pretax Margin (Annual)-71.58%
Cash / Share (Annual)$0.01
3-Month Return Std Dev86.64%
Gross Margin (5Y Avg)72.65%
Net Income / Employee (TTM)$-0
ROE (Last FY)-64.64%
Net Interest Coverage (Annual)-9.10x
EPS Basic Excl Extra (Annual)$-0.02
Receivables Turnover (TTM)3.14x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)4.40x
ROI (TTM)-43.95%
P/S Ratio (TTM)1.22x
Pretax Margin (5Y Avg)-1309.47%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.06
Price vs S&P 500 (52W)7.52%
Year-to-Date Return-19.44%
5-Day Price Return7.41%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-31.16%
Net Profit Margin (Annual)-71.58%
Month-to-Date Return3.57%
EBITD / Share (Annual)$-0.02
Operating Margin (Annual)-73.34%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-36.64%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)2.21x
P/B Ratio (Annual)1.77x
Inventory Turnover (TTM)1.44x
Pretax Margin (TTM)-62.14%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-20.13%
Beta1.80x
Revenue / Share (TTM)$0.02
ROE (TTM)-43.95%
52-Week Low$0.03
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMRNImmuron Limited American Depositary Shares | 1.22x | 14.30% | 63.68% | — | $0.84 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Immuron Ltd is a biopharmaceutical company specializing in polyclonal antibody therapeutics for gastrointestinal and enteric diseases. It markets Travelan for travelers' diarrhea prevention and Protectyn as an immune supplement, while advancing two clinical-stage candidates (IMM124-E and IMM529) toward commercialization. The company generates revenue primarily from Australia, the USA, and Canada through its hyper-immune products segment.